Zeenat Qureshi Stroke Research Center, Department of Neurology, University of Minnesota, Minneapolis, USA.
J Neurosurg. 2011 Mar;114(3):834-41. doi: 10.3171/2010.6.JNS091486. Epub 2010 Jul 23.
The utilization of endovascular treatment for ruptured intracranial aneurysms is expected to change since the publication of the International Subarachnoid Aneurysm Trial (ISAT) in 2002. The authors performed this analysis to determine the impact of ISAT results on treatment selection for ruptured intracranial aneurysms and associated in-hospital outcomes using nationally representative data.
We determined the national estimates of treatments used for ruptured intracranial aneurysms and associated in-hospital outcomes, length of stay, mortality, and cost incurred using the Nationwide Inpatient Survey (NIS) data. The NIS is the largest all-payer inpatient care database in the US and contains data from 986 hospitals approximating a 20% stratified sample of US hospitals. All the variables pertaining to hospitalization were compared between 2000-2002 and 2004-2006, and in-hospital outcomes were analyzed using multivariate analysis.
In the 3-year periods prior to and after the ISAT, there were 70,637 and 77,352 admissions for ruptured intracranial aneurysms, respectively. There was a significant increase in endovascular treatment after publication of the ISAT (trend test, p < 0.0001) The in-hospital mortality for ruptured intracranial aneurysm admissions decreased from 27% to 24% (odds ratio [OR] 0.89, 95% CI 0.83-0.96, p = 0.003) after the publication of the ISAT. The cost of hospitalization after adjusting for procedures practices was not significantly higher after the publication of the ISAT ($21,437 vs $22,817, p < 0.89), but cost of hospitalization was higher in the post-ISAT period for patients undergoing endovascular procedure.
The results of the ISAT have been associated with a prominent change in practice patterns related to the treatment of ruptured aneurysms. The cost of hospitalization has increased and the mortality has decreased, presumably due to a larger proportion of patients receiving any treatment and endovascular treatment.
自 2002 年国际蛛网膜下腔出血试验(ISAT)发表以来,预计对破裂颅内动脉瘤的血管内治疗的利用会发生变化。作者进行了这项分析,以使用全国代表性数据确定 ISAT 结果对破裂颅内动脉瘤的治疗选择和相关住院治疗结果的影响。
我们使用全国住院患者调查(NIS)数据确定了用于破裂颅内动脉瘤和相关住院治疗结果、住院时间、死亡率和费用的全国治疗估计数。NIS 是美国最大的全支付住院患者护理数据库,包含来自 986 家医院的数据,这些数据约占美国医院的 20%分层样本。将 2000-2002 年和 2004-2006 年期间的所有与住院相关的变量进行比较,并使用多元分析分析住院治疗结果。
在 ISAT 发表前后的 3 年期间,分别有 70637 例和 77352 例患者因破裂颅内动脉瘤入院。ISAT 发表后,血管内治疗显著增加(趋势检验,p < 0.0001)。ISAT 发表后,破裂颅内动脉瘤入院的住院死亡率从 27%降至 24%(比值比 [OR] 0.89,95%置信区间 [CI] 0.83-0.96,p = 0.003)。调整程序实践后,住院费用在 ISAT 发表后并没有显著增加($21437 与 $22817,p < 0.89),但接受血管内治疗的患者在 ISAT 发表后住院费用更高。
ISAT 的结果与与治疗破裂动脉瘤相关的实践模式的显著变化有关。住院费用增加,死亡率下降,这可能是由于接受任何治疗和血管内治疗的患者比例增加所致。